BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lenalidomide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Lenalidomide\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03980171-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT03980171)
DESCRIPTION:Lenalidomide\, phase 1/2\, Follicular Lymphoma.\nStudy: Study o
 f Lenalidomide\, Venetoclax and Obinutuzumab in Patients With Treatment-Na
 ïve Follicular Lymphoma\nEstimated primary completion: November 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT03980171
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06505369-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06505369)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Bispecific T
 -cell Redirectors as Part of First Line Treatment in Transplant Eligible M
 ultiple Myeloma Patients\nEstimated primary completion: November 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06505369
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06517017-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06517017)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Use of Isatu
 ximab\, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frai
 l Patients With Multiple Myeloma\nEstimated primary completion: November 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0651701
 7
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06669143-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06669143)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Zanubrutinib-based Maintenance 
 Therapy of Newly Diagnosed DLBCL With Initial Remission\nEstimated primary
  completion: November 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06669143
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01562405-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lenalidomide: Phase 1 readout est. (NCT01562405)
DESCRIPTION:Lenalidomide\, phase 1\, Multiple Myeloma.\nStudy: Sotatercept 
 (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/
 Refractory Multiple Myeloma\nEstimated primary completion: December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT01562405
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02573896-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lenalidomide: Phase 1 readout est. (NCT02573896)
DESCRIPTION:Lenalidomide\, phase 1.\nStudy: Immunotherapy of Relapsed Refra
 ctory Neuroblastoma With Expanded NK Cells\nEstimated primary completion: 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenali
 domide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT02573896
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04009109-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT04009109)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Study of Lenalidomide/Ixazomib/
 Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Dia
 gnosed MM\nEstimated primary completion: December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04009109
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05979363-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT05979363)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: A Study of Bortezomib\, Lenalid
 omide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy
  in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia\nEsti
 mated primary completion: 1 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05979363
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06549335-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06549335)
DESCRIPTION:Lenalidomide\, phase 2\, Follicular Lymphoma.\nStudy: Zanubruti
 nib\, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Pat
 ients with Follicular Lymphoma (FL)\nEstimated primary completion: 1 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomid
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 549335
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05950165-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT05950165)
DESCRIPTION:Lenalidomide\, phase 1/2.\nStudy: A Study to Assess Safety and 
 Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjec
 ts With Refractory or Relapsed Non-Hodgkin's Lymphoma\nEstimated primary c
 ompletion: 23 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05950165
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03729804-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT03729804)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Carfilzomib\
 , Lenalidomide\, and Dexamethasone Versus Bortezomib\, Lenalidomide and De
 xamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myelom
 a (COBRA)\nEstimated primary completion: 28 December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03729804
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05449548-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Lenalidomide: Phase na readout est. (NCT05449548)
DESCRIPTION:Lenalidomide\, phase na.\nStudy: Lenalidomide in the Treatment 
 of Mucosal Behçet's Syndrome\nEstimated primary completion: 30 December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0544954
 8
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01863550-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT01863550)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Bortezomib o
 r Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients Wit
 h Newly Diagnosed Multiple Myeloma\nEstimated primary completion: 31 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomid
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT01
 863550
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05351593-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT05351593)
DESCRIPTION:Lenalidomide\, phase 1/2.\nStudy: Tafasitamab Plus Lenalidomide
  in Relapsed CNS Lymphoma\nEstimated primary completion: 31 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05351593
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06504199-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06504199)
DESCRIPTION:Lenalidomide\, phase 2\, Mantle Cell Lymphoma.\nStudy: Obinutuz
 umab\, Zanubrutinib\, and Lenalidomide Followed Short-Cycle of Obinutuzuma
 b and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma\nEstimated primar
 y completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06504199
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06697483-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lenalidomide: Phase na readout est. (NCT06697483)
DESCRIPTION:Lenalidomide\, phase na\, Multiple Myeloma.\nStudy: Risk Strati
 fication and MRD-driven Maintenance for MM After ASCT\nEstimated primary c
 ompletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06697483
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05828459-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Lenalidomide: Phase 1 readout est. (NCT05828459)
DESCRIPTION:Lenalidomide\, phase 1.\nStudy: First-in-human Study of OT-A201
  in Patients With Selected Hematological Malignancies and Solid Tumors\nEs
 timated primary completion: January 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05828459
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06760156-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06760156)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Tafasitamab and Lenalidomide as
  First Salvage Therapy for Residual Large B Cell Lym\nEstimated primary co
 mpletion: January 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06760156
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03829371-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270103
DTEND;VALUE=DATE:20270104
SUMMARY:Lenalidomide: Phase 4 readout est. (NCT03829371)
DESCRIPTION:Lenalidomide\, phase 4\, Multiple Myeloma.\nStudy: STUDY COMPAR
 ING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIG
 IBLE POPULATION AFFECTED BY MULTIPLE MYELOMA\nEstimated primary completion
 : 3 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/len
 alidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT03829371
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04978584-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270116
DTEND;VALUE=DATE:20270117
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT04978584)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Rituximab\, Lenalidomide\, Acal
 abrutinib\, Tafasitamab Alone and With Combination Chemotherapy for the Tr
 eatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lympho
 ma\, Smart Stop Study\nEstimated primary completion: 16 January 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04978584
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05583071-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT05583071)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Methotrexate\, Tafasitamab\, Le
 nalidomide and Rituximab in Patients With PCNSL\nEstimated primary complet
 ion: February 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/l
 enalidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05583071
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04268498-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT04268498)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: A Study of D
 aratumumab\, Carfilzomib\, Lenalidomide\, and Dexamethasone in Patients Wi
 th Newly-Diagnosed Multiple Myeloma\nEstimated primary completion: 1 Febru
 ary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomid
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 268498
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05861050-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT05861050)
DESCRIPTION:Lenalidomide\, phase 1/2\, Mantle Cell Lymphoma.\nStudy: Glofit
 amab With Obinutuzumab\, Venetoclax\, and Lenalidomide for the Treatment o
 f Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma\nEstimated 
 primary completion: 1 February 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05861050
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02886065-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270215
DTEND;VALUE=DATE:20270216
SUMMARY:Lenalidomide: Phase 1 readout est. (NCT02886065)
DESCRIPTION:Lenalidomide\, phase 1\, Multiple Myeloma.\nStudy: A Study of P
 VX-410\, a Cancer Vaccine\, and Citarinostat +/- Lenalidomide for Smolderi
 ng MM\nEstimated primary completion: 15 February 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT02886065
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06723457-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270218
DTEND;VALUE=DATE:20270219
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06723457)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Epcoritamab and Lenalidomide in
  Treating Patients With Refractory or Relapsed Immunodeficiency-Related La
 rge B-Cell Lymphoma\nEstimated primary completion: 18 February 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06723457
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04133636-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT04133636)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: A Study of J
 NJ-68284528\, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed 
 Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Mye
 loma\nEstimated primary completion: 26 February 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04133636
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07884708-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270311
DTEND;VALUE=DATE:20270312
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07884708)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Chidamide\, Lenalidomide\, and 
 Rituximab in Newly Diagnosed Elderly/unFit DE-DLBCL\nEstimated primary com
 pletion: 11 March 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07884708
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04068597-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT04068597)
DESCRIPTION:Lenalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: Study to E
 valuate CCS1477 (Inobrodib) in Haematological Malignancies\nEstimated prim
 ary completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04068597
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06863584-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06863584)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: SBRT Plus Lenalidomide for Soli
 tary Plasmacytoma: Phase II Trial\nEstimated primary completion: 31 March 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT068635
 84
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02343042-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT02343042)
DESCRIPTION:Lenalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: Selinexor 
 and Backbone Treatments of Multiple Myeloma Patients\nEstimated primary co
 mpletion: April 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /lenalidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT02343042
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05558319-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT05558319)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: NDMM Patient
 s Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Ib
 erdomide\nEstimated primary completion: April 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05558319
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05260619-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT05260619)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Lenalidomide Maintenance Treatm
 ent in Patients With Primary Central Nervous System Lymphoma\nEstimated pr
 imary completion: 1 April 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05260619
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03319667-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270405
DTEND;VALUE=DATE:20270406
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT03319667)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study to I
 nvestigate the Clinical Benefit of Isatuximab in Combination With Bortezom
 ib\, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multipl
 e Myeloma Not Eligible for Transplant\nEstimated primary completion: 5 Apr
 il 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT033
 19667
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07081022-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270406
DTEND;VALUE=DATE:20270407
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07081022)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: JS203 Combination Regimens in B
 -Cell Non-Hodgkin's Lymphoma\nEstimated primary completion: 6 April 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07081022
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07187167-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270412
DTEND;VALUE=DATE:20270413
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07187167)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Efficacy and Safety of the RD R
 egimen(Lenalidomide\, Dexamethasone) for Rosai-Dorfman Disease\nEstimated 
 primary completion: 12 April 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07187167
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02420860-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT02420860)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Elotuzumab a
 nd Lenalidomide After Stem Cell Transplant in Treating Patients With Newly
  Diagnosed Multiple Myeloma\nEstimated primary completion: 30 April 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT02420860
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06087653-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT06087653)
DESCRIPTION:Lenalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: Safety\, E
 fficacy\, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in 
 Multiple Myeloma (MM)\nEstimated primary completion: 31 May 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06087653
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01297764-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT01297764)
DESCRIPTION:Lenalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: A Study of
  Carfilzomib\, Lenalidomide\, Vorinostat\, and Dexamethasone in Relapsed a
 nd/or Refractory Multiple Myeloma\nEstimated primary completion: June 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT01297764
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05572229-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT05572229)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Study of Tec
 listamab in Combination in Elderly Patients With Multiple Myeloma\nEstimat
 ed primary completion: June 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05572229
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03523975-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270624
DTEND;VALUE=DATE:20270625
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT03523975)
DESCRIPTION:Lenalidomide\, phase 1/2\, Mantle Cell Lymphoma.\nStudy: Veneto
 clax\, Lenalidomide and Rituximab in Patients With Previously Untreated Ma
 ntle Cell Lymphoma\nEstimated primary completion: 24 June 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT03523975
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04301076-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Lenalidomide: Phase 1 readout est. (NCT04301076)
DESCRIPTION:Lenalidomide\, phase 1.\nStudy: Testing the Addition of an Anti
 -cancer Drug\, Lenalidomide\, to the Usual Combination Chemotherapy Treatm
 ent ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)\nEstimated primary
  completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04301076
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06015880-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Lenalidomide: Phase 1 readout est. (NCT06015880)
DESCRIPTION:Lenalidomide\, phase 1.\nStudy: Testing the Combination of Anti
 -cancer Drugs Mosunetuzumab\, Polatuzumab Vedotin\, and Lenalidomide for t
 he Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma\nEstimat
 ed primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06015880
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03556332-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT03556332)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: A Study of C
 arfilzomib\, Lenalidomide\, Dexamethasone and Daratumumab for Patients Wit
 h Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell T
 ransplantation\nEstimated primary completion: July 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT03556332
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07261163-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07261163)
DESCRIPTION:Lenalidomide\, phase 2\, Mantle Cell Lymphoma.\nStudy: Obinutuz
 umab\, Zanubrutinib\, and Lenalidomide in First-line Treatment of Mantle C
 ell Lymphoma\nEstimated primary completion: 31 July 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07261163
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02538198-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT02538198)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Lenalidomide
  Maintenance in Plasma Cell Myeloma\nEstimated primary completion: August 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT025381
 98
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04497961-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT04497961)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: A Study of H
 ealth-Related Quality of Life in People With Multiple Myeloma Receiving Da
 ratumumab or Lenalidomide\nEstimated primary completion: August 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04497961
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05665140-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Lenalidomide: Phase 2/3 readout est. (NCT05665140)
DESCRIPTION:Lenalidomide\, phase 2/3\, Multiple Myeloma.\nStudy: Expression
 -linked and R-ISS-adapted Stratification for First Line Therapy in Multipl
 e Myeloma Patients\nEstimated primary completion: August 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05665140
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04609046-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Lenalidomide: Phase 1 readout est. (NCT04609046)
DESCRIPTION:Lenalidomide\, phase 1.\nStudy: Testing the Addition of Lenalid
 omide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma\nEstim
 ated primary completion: 1 August 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04609046
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06112847-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06112847)
DESCRIPTION:Lenalidomide\, phase 2\, Follicular Lymphoma.\nStudy: Lenalidom
 ide and Epcoritamab for the Treatment of Previously Untreated Follicular L
 ymphoma\nEstimated primary completion: 10 August 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06112847
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07697339-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Lenalidomide: Phase 1 readout est. (NCT07697339)
DESCRIPTION:Lenalidomide\, phase 1\, Mantle Cell Lymphoma.\nStudy: HDM2005 
 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma\nEstimated
  primary completion: 10 August 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07697339
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03223610-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270812
DTEND;VALUE=DATE:20270813
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT03223610)
DESCRIPTION:Lenalidomide\, phase 1/2.\nStudy: Venetoclax\, Ibrutinib\, Pred
 nisone\, Obinutuzumab\, and Revlimid (ViPOR) in Relapsed/Refractory B-cell
  Lymphoma\nEstimated primary completion: 12 August 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT03223610
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05615636-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270819
DTEND;VALUE=DATE:20270820
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT05615636)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: A Phase II Trial of Mosunetuzum
 ab\, Polatuzumab\, Tafasitamab\, and Lenalidomide in Patients With Relapse
 d B-cell NHL\nEstimated primary completion: 19 August 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05615636
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04792502-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT04792502)
DESCRIPTION:Lenalidomide\, phase 2\, Follicular Lymphoma.\nStudy: Mosunetuz
 umab With Lenalidomide Augmentation as First-line Therapy for Follicular a
 nd Marginal Zone Lymphoma\nEstimated primary completion: 31 August 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04792502
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06151080-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06151080)
DESCRIPTION:Lenalidomide\, phase 2\, Follicular Lymphoma.\nStudy: Lenalidom
 ide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
 \nEstimated primary completion: 31 August 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06151080
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04542824-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT04542824)
DESCRIPTION:Lenalidomide\, phase 1/2\, Follicular Lymphoma.\nStudy: Trial o
 f the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapse
 d or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)\nEstimated p
 rimary completion: September 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04542824
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06006117-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT06006117)
DESCRIPTION:Lenalidomide\, phase 3.\nStudy: Mosunetuzumab-Lenalidomide Vers
 us Investigator Choices in Patients With Relapsed or Refractory Marginal Z
 one Lymphoma\nEstimated primary completion: September 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06006117
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04096066-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT04096066)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Trial That
  Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible f
 or Transplant\nEstimated primary completion: 1 September 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04096066
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07133763-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT07133763)
DESCRIPTION:Lenalidomide\, phase 1/2.\nStudy: Application of PD-1 Inhibitor
 s\, Tenofovir\, Chidamide\, and Lenalidomide in Relapsed/Refractory EBV-as
 sociated Lymphoproliferative Disorders.\nEstimated primary completion: 1 S
 eptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenali
 domide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07133763
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07133776-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT07133776)
DESCRIPTION:Lenalidomide\, phase 1/2.\nStudy: Application of PD-1 Inhibitor
 s Combined With Tenofovir\, Chidamide and Lenalidomide in the Treatment of
  EBV-associated Diseases.\nEstimated primary completion: 1 September 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07133776
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04635189-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270908
DTEND;VALUE=DATE:20270909
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT04635189)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Steroid Spar
 ing Treatment With in Newly Diagnosed Transplant Ineligible Patients With 
 Multiple Myeloma\nEstimated primary completion: 8 September 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04635189
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04663347-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT04663347)
DESCRIPTION:Lenalidomide\, phase 1/2\, Follicular Lymphoma.\nStudy: Safety 
 and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non
 -Hodgkin Lymphoma (B-NHL)\nEstimated primary completion: 30 September 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04663347
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05683171-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT05683171)
DESCRIPTION:Lenalidomide\, phase 1/2\, Follicular Lymphoma.\nStudy: A Phase
  1/2\, Open-label Study of Valemetostat in Combination With Rituximab and 
 Lenalidomide in Relapsed or Refractory Follicular Lymphoma\nEstimated prim
 ary completion: 30 September 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05683171
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03004287-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT03004287)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: 2015-12: A S
 tudy Exploring the Use of Early and Late Consolidation/Maintenance Therapy
 \nEstimated primary completion: October 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03004287
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05201248-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT05201248)
DESCRIPTION:Lenalidomide\, phase 1/2.\nStudy: A Study to Evaluate Adverse E
 vents and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As M
 onotherapy or Combined With Standard of Care Therapies in Adult Participan
 ts in China With B-Cell Non-Hodgkin Lymphoma\nEstimated primary completion
 : October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenal
 idomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05201248
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07839247-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07839247)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Zanubrutinib Plus Lenalidomide 
 for Frail Elderly Patients With Newly Diagnosed PCNSL\nEstimated primary c
 ompletion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07839247
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07789522-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271009
DTEND;VALUE=DATE:20271010
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07789522)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Safety and E
 fficacy of Elranatamab Plus Isatuximab\, Bortezomib\, and Lenalidomide in 
 Ultra-High-Risk Multiple Myeloma\nEstimated primary completion: 9 October 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077895
 22
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07828522-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271009
DTEND;VALUE=DATE:20271010
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07828522)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: F182112 in C
 ombination With Isatuximab and Lenalidomide for the Treatment of Patients 
 With Newly Diagnosed Multiple Myeloma\nEstimated primary completion: 9 Oct
 ober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomi
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7828522
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02659293-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT02659293)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Trial of Car
 filzomib\, Lenalidomide\, Dexamethasone Versus Lenalidomide Alone After St
 em-cell Transplant for Multiple Myeloma\nEstimated primary completion: Nov
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidom
 ide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 02659293
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018050-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07018050)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Phase II Stu
 dy of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma\nE
 stimated primary completion: November 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07018050
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06409702-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Lenalidomide: Phase 4 readout est. (NCT06409702)
DESCRIPTION:Lenalidomide\, phase 4\, Multiple Myeloma.\nStudy: Treatment of
  High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease 
 Detection\nEstimated primary completion: 30 November 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06409702
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07210047-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT07210047)
DESCRIPTION:Lenalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: Study of H
 uL001 in Relapsed/Refractory Multiple Myeloma Patients\nEstimated primary 
 completion: 30 November 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07210047
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04623541-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT04623541)
DESCRIPTION:Lenalidomide\, phase 1/2.\nStudy: Safety and Efficacy Study of 
 Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leuke
 mia and Richter's Syndrome\nEstimated primary completion: December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04623541
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04891809-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT04891809)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab i
 n Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years
 ) With NDMM\nEstimated primary completion: December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04891809
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06461988-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06461988)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Talquetamab 
 & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myelom
 a\nEstimated primary completion: December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06461988
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07297329-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT07297329)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study to E
 valuate the Safety and Efficacy of SCTC21C in Combination With Bortezomib\
 , Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple
  Myeloma Not Eligible for Transplant\nEstimated primary completion: Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT072
 97329
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04775550-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271220
DTEND;VALUE=DATE:20271221
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT04775550)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: DARA RVD For
  High Risk SMM\nEstimated primary completion: 20 December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT04775550
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07460362-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07460362)
DESCRIPTION:Lenalidomide\, phase 2\, Mantle Cell Lymphoma.\nStudy: Glofitam
 ab Combined With Lenalidomide in High Risk Patients With Relapsed or Refra
 ctory Mantle Cell Lymphoma\nEstimated primary completion: 30 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07460362
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03376672-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT03376672)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Ixazomib Plu
 s Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients\nEs
 timated primary completion: 31 December 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03376672
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04566328-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT04566328)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Testing the 
 Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple
  Myeloma\, the EQUATE Trial\nEstimated primary completion: 31 December 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04566328
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05091372-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT05091372)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Minimal Resi
 dual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lena
 lidomide After Autologous Hematopoietic Cell Transplantation in Patients W
 ith Newly Diagnosed Multiple Myeloma\nEstimated primary completion: 31 Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidom
 ide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05091372
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05776979-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT05776979)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Post-Transpl
 ant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Mu
 ltiple Myeloma Patients\nEstimated primary completion: 31 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05776979
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06441097-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06441097)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Efficacy of Pola-RCHP-X vs Pola
 -RCHP in Untreated DLBCL\nEstimated primary completion: 31 December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06441097
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06651853-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06651853)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Large Fraction Radiation Therap
 y Combined With Lenalidomide\, and Glofitamab in Refractory Relapsed DLBCL
 \nEstimated primary completion: 31 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06651853
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07418190-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07418190)
DESCRIPTION:Lenalidomide\, phase 2\, Follicular Lymphoma.\nStudy: Efficacy 
 and Safety of Zanubrutinib\, Rituximab\, and Lenalidomide (ZR²) in Combin
 ation With Tislelizumab for Relapsed/Refractory Follicular Lymphoma\nEstim
 ated primary completion: 31 December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07418190
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06744894-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06744894)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: SIL as Maint
 enance Therapy in Multiple Myeloma\nEstimated primary completion: 1 Januar
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0674
 4894
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07448324-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07448324)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Orelabrutinib Combined With Rit
 uximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreate
 d MZL\nEstimated primary completion: 1 January 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07448324
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06192888-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280108
DTEND;VALUE=DATE:20280109
SUMMARY:Lenalidomide: Phase 1 readout est. (NCT06192888)
DESCRIPTION:Lenalidomide\, phase 1\, Mantle Cell Lymphoma.\nStudy: A Study 
 of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma\nEstima
 ted primary completion: 8 January 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06192888
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06508658-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT06508658)
DESCRIPTION:Lenalidomide\, phase 3.\nStudy: A Study of Subcutaneously Injec
 ted Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (
 IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplat
 in in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell 
 Lymphoma\nEstimated primary completion: March 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06508658
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04404088-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT04404088)
DESCRIPTION:Lenalidomide\, phase 2\, Follicular Lymphoma.\nStudy: Acalabrut
 inib\, Lenalidomide\, and Rituximab for the Treatment of CD20 Positive Sta
 ge III-IV\, Grade 1-3a Follicular Lymphoma\nEstimated primary completion: 
 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalid
 omide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04404088
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05025800-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT05025800)
DESCRIPTION:Lenalidomide\, phase 1/2\, Follicular Lymphoma.\nStudy: ALX148\
 , Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive 
 B-cell Non-Hodgkin Lymphoma\nEstimated primary completion: 21 March 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05025800
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05137054-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280325
DTEND;VALUE=DATE:20280326
SUMMARY:Lenalidomide: Phase 1 readout est. (NCT05137054)
DESCRIPTION:Lenalidomide\, phase 1\, Multiple Myeloma.\nStudy: A Study to E
 xamine the Effects of Novel Therapy Linvoseltamab in Combination With Othe
 r Cancer Treatments for Adult Participants With Multiple Myeloma That is R
 esistant to Current Standard of Care Treatments\nEstimated primary complet
 ion: 25 March 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/l
 enalidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05137054
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07045909-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07045909)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Efficacy and
  Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed 
 Multiple Myeloma (GEM-AnitoFIRST)\nEstimated primary completion: 31 March 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070459
 09
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07341867-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Lenalidomide: Phase 1 readout est. (NCT07341867)
DESCRIPTION:Lenalidomide\, phase 1\, Multiple Myeloma.\nStudy: Systemic Ant
 i-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenot
 ype\nEstimated primary completion: 31 March 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07341867
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06353022-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280426
DTEND;VALUE=DATE:20280427
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06353022)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Minimal Resi
 dual Disease-based Strategy With T-Cell Redirector After Treatment With Da
 ratumumab\, Bortezomib\, Lenalidomide\, and Dexamethasone (D-VRd) in Newly
  Diagnosed Multiple Myeloma\nEstimated primary completion: 26 April 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06353022
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07299149-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280428
DTEND;VALUE=DATE:20280429
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07299149)
DESCRIPTION:Lenalidomide\, phase 2\, Follicular Lymphoma.\nStudy: Zanubruti
 nib\, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of U
 ntreated Follicular Lymphoma\nEstimated primary completion: 28 April 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07299149
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06803693-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06803693)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Efficacy and Safety of Pola-RCH
 P-X vs Pola-RCHP in Untreated DLBCL\nEstimated primary completion: 30 Apri
 l 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0680
 3693
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05846880-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Lenalidomide: Phase 1 readout est. (NCT05846880)
DESCRIPTION:Lenalidomide\, phase 1\, Multiple Myeloma.\nStudy: VitD3 Supple
 mentation in Patients With Multiple Myeloma\nEstimated primary completion:
  May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomi
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5846880
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07485647-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07485647)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Identifying 
 Effective and Cost-Conscious Maintenance Daratumumab Dosing\nEstimated pri
 mary completion: May 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07485647
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07562022-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT07562022)
DESCRIPTION:Lenalidomide\, phase 3\, Follicular Lymphoma.\nStudy: A Study t
 o Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidom
 ide in Patients With Relapsed or Refractory Follicular Lymphoma\nEstimated
  primary completion: May 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07562022
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07926893-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280516
DTEND;VALUE=DATE:20280517
SUMMARY:Lenalidomide: Phase 1 readout est. (NCT07926893)
DESCRIPTION:Lenalidomide\, phase 1.\nStudy: Lenalidomide and Cosibelimab fo
 r the Treatment of Relapsed/Refractory Mycosis Fungoides or Sézary Syndro
 me\nEstimated primary completion: 16 May 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07926893
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03617731-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT03617731)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Trial on the
  Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induc
 tion and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma
  (GMMG HD7)\nEstimated primary completion: June 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT03617731
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07384624-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT07384624)
DESCRIPTION:Lenalidomide\, phase 1/2.\nStudy: Combining Latency Reversing A
 gents to Address the HIV Reservoir\nEstimated primary completion: June 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07384624
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07560449-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07560449)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: QLS4131 Combination Therapy in 
 Malignant Plasma Cell Neoplasms\nEstimated primary completion: June 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07560449
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07208981-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07208981)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Orelabrutinib Combined With Zeb
 etuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL\nEstima
 ted primary completion: 1 June 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07208981
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01446133-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT01446133)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Combination of Lenalidomide and
  Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL
 -SLL)\nEstimated primary completion: 30 June 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT01446133
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07639138-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07639138)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Lenalidomide Plus Targeted Ther
 apy and Immunotherapy for Refractory HCC\nEstimated primary completion: 30
  June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidom
 ide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07639138
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07334535-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Lenalidomide: Phase 4 readout est. (NCT07334535)
DESCRIPTION:Lenalidomide\, phase 4\, Multiple Myeloma.\nStudy: Isa-VRD in T
 IE HRMM\nEstimated primary completion: July 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07334535
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07814001-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07814001)
DESCRIPTION:Lenalidomide\, phase 2\, Follicular Lymphoma.\nStudy: Epcoritam
 ab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Se
 cond-Line CAR T-cell Therapy\nEstimated primary completion: July 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07814001
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07068165-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280720
DTEND;VALUE=DATE:20280721
SUMMARY:Lenalidomide: Phase 2/3 readout est. (NCT07068165)
DESCRIPTION:Lenalidomide\, phase 2/3.\nStudy: A Randomized Controlled Study
  of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG
 4-related Disease\nEstimated primary completion: 20 July 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07068165
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05583617-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT05583617)
DESCRIPTION:Lenalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: A Study Ev
 aluating the Safety and Efficacy of Multiple Treatments in Participants Wi
 th Multiple Myeloma\nEstimated primary completion: 31 July 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05583617
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06522555-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280810
DTEND;VALUE=DATE:20280811
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT06522555)
DESCRIPTION:Lenalidomide\, phase 3.\nStudy: The Efficacy and Safety of Pola
 -ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Larg
 e B-cell Lymphoma\nEstimated primary completion: 10 August 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06522555
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07308132-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Lenalidomide: Phase 1 readout est. (NCT07308132)
DESCRIPTION:Lenalidomide\, phase 1.\nStudy: A Study of JNJ-95566692 in Part
 icipants With Non-Hodgkin Lymphoid Malignancies\nEstimated primary complet
 ion: 31 August 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 lenalidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07308132
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06521255-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT06521255)
DESCRIPTION:Lenalidomide\, phase 3.\nStudy: Evaluate the Safety and Efficac
 y of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxal
 iplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin i
 n Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma\nEstimat
 ed primary completion: September 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06521255
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06649812-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06649812)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Testing the Effectiveness of a 
 Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Ref
 ractory Aggressive B-cell Lymphoma\nEstimated primary completion: 1 Septem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomid
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 649812
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05695508-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT05695508)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: GMMG-HD10 / 
 DSMM-XX / 64007957MMY2003\, MajesTEC-5\nEstimated primary completion: 15 S
 eptember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenali
 domide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05695508
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06516978-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06516978)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: A Study Comparing the Efficacy 
 and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untre
 ated Patients With DLBCL\nEstimated primary completion: 1 October 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06516978
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07917624-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07917624)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Prophylactic Strategies for Mit
 igating Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma\nE
 stimated primary completion: 31 October 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07917624
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06284122-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT06284122)
DESCRIPTION:Lenalidomide\, phase 3\, Follicular Lymphoma.\nStudy: Study of 
 Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemothe
 rapy in Follicular Lymphoma FLIPI2-5\nEstimated primary completion: Novemb
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT062
 84122
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04627753-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20281102
DTEND;VALUE=DATE:20281103
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT04627753)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Study of Lenalidomide/Rituximab
  Maintenance for Transplantation Ineligible Patients With PCNSL.\nEstimate
 d primary completion: 2 November 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04627753
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07735637-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20281102
DTEND;VALUE=DATE:20281103
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT07735637)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Phase III\
 , Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compa
 red With ASCT\, in Participants With Newly Diagnosed Multiple Myeloma Who 
 Are Transplant Eligible (DURGA-6).\nEstimated primary completion: 2 Novemb
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077
 35637
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05669989-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT05669989)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Internationa
 l Treatment-extension Study in Adult Participants With Multiple Myeloma an
 d Who Have Derived Clinical Benefit From Isatuximab\nEstimated primary com
 pletion: 30 November 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05669989
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06931704-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06931704)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Comparison o
 f Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post
 -transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (
 ElMMA)\nEstimated primary completion: 30 November 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06931704
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07938619-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07938619)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Tafasitamab\, Lenalidomide\, Ri
 tuximab\, and Orelabrutinib for Patients With Relapsed or Refractory Diffu
 se Large B-Cell Lymphoma\nEstimated primary completion: 1 December 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07938619
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06220032-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20281215
DTEND;VALUE=DATE:20281216
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT06220032)
DESCRIPTION:Lenalidomide\, phase 3.\nStudy: Prevention of Anthracycline-Ind
 uced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B
  Cell Lymphoma\nEstimated primary completion: 15 December 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06220032
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07240194-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07240194)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: The Efficacy and Safety of Glof
 itamab in Combination With PD-1 Antibody and Lenalidomide in Patients With
  Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A
  Prospective\, Multicenter\, Phase II Clinical Study\nEstimated primary co
 mpletion: 30 December 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07240194
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06793189-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06793189)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: MZL-IPI Risk-adapted Targeted T
 herapy in Untreated MZL\nEstimated primary completion: 31 December 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06793189
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07165769-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07165769)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Zanubrutinib\, Obinutuzumab\, a
 nd Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell L
 ymphoma With Prominent Nucleoli (SBLPN): A Prospective\, Open-label\, Sing
 le-arm Clinical Trial\nEstimated primary completion: 31 December 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07165769
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07514169-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07514169)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: The Efficacy and Safety of Pola
 -ZR-Glo in Older Treatment-naive Patients With LBCL\nEstimated primary com
 pletion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07514169
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621406-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07621406)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Efficacy and Safety of Sequenti
 al Autologous Hematopoietic Stem Cell Transplantation Combined With Tafasi
 tamab\, Lenalidomide\, and Standard Immunochemotherapy for Relapsed/Refrac
 tory Diffuse Large B-cell Lymphoma\nEstimated primary completion: 31 Decem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomid
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 621406
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07709884-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Lenalidomide: Phase 4 readout est. (NCT07709884)
DESCRIPTION:Lenalidomide\, phase 4\, Multiple Myeloma.\nStudy: A Single-cen
 ter\, Prospective\, Single-arm Clinical Study Exploring the Treatment of N
 ewly Diagnosed Multiple Myeloma Patients With t(11\;14) Suitable for Trans
 plantation Using the SonKRd Regimen\nEstimated primary completion: 31 Dece
 mber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomi
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7709884
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07913594-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07913594)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Zilovertamab Vedotin and Lenali
 domide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell Lymphoma
 \nEstimated primary completion: 31 December 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07913594
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06665217-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06665217)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: G-Pola-ZLP in Diffuse Large B-C
 ell Lymphoma\nEstimated primary completion: January 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06665217
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06768489-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290102
DTEND;VALUE=DATE:20290103
SUMMARY:Lenalidomide: Phase 1 readout est. (NCT06768489)
DESCRIPTION:Lenalidomide\, phase 1\, Multiple Myeloma.\nStudy: A Study of R
 amantamig in Combination With Daratumumab With or Without Lenalidomide or 
 of Single-agent JNJ-102299639 for Multiple Myeloma\, Newly Diagnosed AL Am
 yloidosis\, and High-risk Smoldering Multiple Myeloma or Ramantamig in Com
 bination With Pomalidomide for Multiple Myeloma\nEstimated primary complet
 ion: 2 January 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 lenalidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06768489
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07764978-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290111
DTEND;VALUE=DATE:20290112
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT07764978)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Study of AZD
 0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT\nEstimated pr
 imary completion: 11 January 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07764978
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05438043-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT05438043)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study of D
 aratumumab\nEstimated primary completion: 31 January 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05438043
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06965244-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT06965244)
DESCRIPTION:Lenalidomide\, phase 3.\nStudy: Lenalidomide vs Methotrexate in
  Difficult-to-treat Cutaneous Lupus Erythematosus\nEstimated primary compl
 etion: 1 February 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06965244
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04923893-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290214
DTEND;VALUE=DATE:20290215
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT04923893)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study of B
 ortezomib\, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel\, a
  CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide a
 nd Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multipl
 e Myeloma for Whom ASCT is Not Planned as Initial Therapy\nEstimated prima
 ry completion: 14 February 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04923893
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04822337-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT04822337)
DESCRIPTION:Lenalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: Study of C
 arfilzomib\, Lenalidomide\, Dexamethasone and Belantamab Mafodotin in Mult
 iple Myeloma\nEstimated primary completion: April 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04822337
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07830485-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290415
DTEND;VALUE=DATE:20290416
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07830485)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: CM336 Plus D
 aratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multi
 ple Myeloma\nEstimated primary completion: 15 April 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07830485
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07891923-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290505
DTEND;VALUE=DATE:20290506
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07891923)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Less Doses o
 f Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple
  Myeloma\nEstimated primary completion: 5 May 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07891923
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04669171-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT04669171)
DESCRIPTION:Lenalidomide\, phase 1/2\, Follicular Lymphoma.\nStudy: A Novel
  Vaccine (EO2463) as Monotherapy and in Combination\, for Treatment of Pat
 ients With Indolent Non-Hodgkin Lymphoma\nEstimated primary completion: 30
  May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomi
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4669171
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05848765-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT05848765)
DESCRIPTION:Lenalidomide\, phase 2\, Follicular Lymphoma.\nStudy: Relapsed 
 Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy\nEstima
 ted primary completion: 31 May 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05848765
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594899-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07594899)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: AI-Driven Treatment Strategy vs
  Pola-R-CHP in Untreated LBCL\nEstimated primary completion: 31 May 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07594899
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07652905-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07652905)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: CM336 Plus Isa-VR in Newly Diag
 nosed Primary Plasma Cell Leukemia\nEstimated primary completion: 30 June 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076529
 05
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07717177-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07717177)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: AI-Driven Treatment Strategy vs
  ZR2 in Older Treatment-naive Patients With LBCL\nEstimated primary comple
 tion: 30 June 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/l
 enalidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07717177
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07906080-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Lenalidomide: Phase 1 readout est. (NCT07906080)
DESCRIPTION:Lenalidomide\, phase 1.\nStudy: Study to Evaluate the Feasibili
 ty and Safety of Autologous Cytokine-Induced Killer Cells (CIK_D332) in Co
 mbination With Tafasitamab and Lenalidomide in Patients With Relapsed or R
 efractory Diffuse Large B-Cell Lymphoma\nEstimated primary completion: 30 
 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomi
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7906080
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06792825-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290708
DTEND;VALUE=DATE:20290709
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06792825)
DESCRIPTION:Lenalidomide\, phase 2\, Follicular Lymphoma.\nStudy: HM2023-43
 :Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive 
 FL and MZL\nEstimated primary completion: 8 July 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06792825
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03948035-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT03948035)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Elotuzumab i
 n Combination With Carfilzomib\, Lenalidomide and Dexamethasone (E-KRd) Ve
 rsus KRd in MM\nEstimated primary completion: August 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03948035
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07072221-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Lenalidomide: Phase na readout est. (NCT07072221)
DESCRIPTION:Lenalidomide\, phase na.\nStudy: Bendamustine Combined With Chi
 damide and Lenalidomide for Relapsed and Refractory PTCL Patients\nEstimat
 ed primary completion: 1 August 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07072221
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05409066-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT05409066)
DESCRIPTION:Lenalidomide\, phase 3\, Follicular Lymphoma.\nStudy: Study of 
 Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Ora
 l Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activit
 y in Adult Participants With Follicular Lymphoma\nEstimated primary comple
 tion: December 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 lenalidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05409066
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06664411-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06664411)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Pola-ZR2P in Previously Untreat
 ed DLBCL\nEstimated primary completion: December 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06664411
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05890352-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT05890352)
DESCRIPTION:Lenalidomide\, phase 2\, Follicular Lymphoma.\nStudy: Study Add
 ing Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Di
 d Not Respond to Treatment\nEstimated primary completion: 1 December 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05890352
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05910801-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT05910801)
DESCRIPTION:Lenalidomide\, phase 2\, Mantle Cell Lymphoma.\nStudy: Tafasita
 mab\, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refract
 ory Mantle Cell Lymphoma\nEstimated primary completion: 30 December 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05910801
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03937635-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT03937635)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Lenalidomide
 \, and Dexamethasone With or Without Daratumumab in Treating Patients With
  High-Risk Smoldering Myeloma\nEstimated primary completion: 31 December 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0393763
 5
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06207799-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06207799)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Pre-transpla
 nt Purging and Post-transplant MRD-guided Maintenance Therapy With Elranat
 amab in Patients With High-risk Multiple Myeloma\nEstimated primary comple
 tion: 31 December 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06207799
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07585747-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07585747)
DESCRIPTION:Lenalidomide\, phase 2\, Follicular Lymphoma.\nStudy: A Explora
 tory Study on Untreated Follicular Lymphoma With Orelabrutinib\, Tafasitam
 ab\, and Lenalidomide\nEstimated primary completion: 31 December 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07585747
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07029776-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20300401
DTEND;VALUE=DATE:20300402
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07029776)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: MMulti-Immun
 e HR\; Multi-Target Immunotherapy for High-Risk Multiple Myeloma\nEstimate
 d primary completion: 1 April 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07029776
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03011814-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20300414
DTEND;VALUE=DATE:20300415
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT03011814)
DESCRIPTION:Lenalidomide\, phase 1/2.\nStudy: Durvalumab With or Without Le
 nalidomide in Treating Patients With Relapsed or Refractory Cutaneous or P
 eripheral T Cell Lymphoma\nEstimated primary completion: 14 April 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT03011814
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07719855-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT07719855)
DESCRIPTION:Lenalidomide\, phase 3\, Follicular Lymphoma.\nStudy: A Multice
 nter\, Prospective\, Open-Label\, Randomized Controlled Clinical Study of 
 Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzu
 mab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma\nEstimated p
 rimary completion: July 2030. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07719855
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06503263-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20300730
DTEND;VALUE=DATE:20300731
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06503263)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Zanubrutinib and Lenalidomide a
 s Maintenance Therapy in DLBCL\nEstimated primary completion: 30 July 2030
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06503263
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06577025-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20300902
DTEND;VALUE=DATE:20300903
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06577025)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: A Study of D
 ifferent Sequences of Cilta-cel\, Talquetamab in Combination With Daratumu
 mab and Teclistamab in Combination With Daratumumab Following Induction Wi
 th Daratumumab\, Bortezomib\, Lenalidomide and Dexamethasone in Participan
 ts With Standard-risk Newly Diagnosed Multiple Myeloma\nEstimated primary 
 completion: 2 September 2030. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06577025
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04246086-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20300906
DTEND;VALUE=DATE:20300907
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT04246086)
DESCRIPTION:Lenalidomide\, phase 1/2\, Follicular Lymphoma.\nStudy: A Study
  Evaluating the Safety\, Pharmacokinetics\, and Efficacy of Mosunetuzumab 
 + Lenalidomide (+Len)\, and the Safety\, Tolerability\, and Pharmacokineti
 cs of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lym
 phoma\nEstimated primary completion: 6 September 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT04246086
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06997081-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06997081)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: ERd Combinat
 ion Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)\nEstimated
  primary completion: 30 September 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06997081
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04270409-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20301014
DTEND;VALUE=DATE:20301015
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT04270409)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Isatuximab i
 n Combination With Lenalidomide and Dexamethasone in High-risk Smoldering 
 Multiple Myeloma\nEstimated primary completion: 14 October 2030. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04270409
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05623020-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20301018
DTEND;VALUE=DATE:20301019
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT05623020)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study to L
 earn About the Effects of the Combination of Elranatamab\, Daratumumab and
  Lenalidomide Compared With Daratumumab\, Bortezomib\, Lenalidomide\, and 
 Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are No
 t Candidates for Transplant\nEstimated primary completion: 18 October 2030
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05623020
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05344833-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT05344833)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Post-Autolog
 ous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Res
 idual Disease Positive Multiple Myeloma\nEstimated primary completion: Dec
 ember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidom
 ide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05344833
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07247097-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20301201
DTEND;VALUE=DATE:20301202
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07247097)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: ELDORADO: El
 ranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagno
 sed Transplant Ineligible/Deferred Multiple Myeloma\nEstimated primary com
 pletion: 1 December 2030. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07247097
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07719543-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT07719543)
DESCRIPTION:Lenalidomide\, phase 3.\nStudy: Efficacy and Safety of Lenalido
 mide in Patients With IgG4-Related Disease\nEstimated primary completion: 
 31 December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/len
 alidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07719543
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06187441-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT06187441)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: FeAsiBility 
 of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With D
 aratumumab-lenalidomide-dexamethasone (HOVON174MM)\nEstimated primary comp
 letion: January 2031. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /lenalidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06187441
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07671287-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20310214
DTEND;VALUE=DATE:20310215
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT07671287)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: GMMG-HD11/DS
 MM XXI/64007957MMY3010\nEstimated primary completion: 14 February 2031. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07671287
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06679101-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20310428
DTEND;VALUE=DATE:20310429
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT06679101)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study of B
 elantamab Mafodotin Administered in Combination With Lenalidomide and Dexa
 methasone (BRd) Versus Daratumumab\, Lenalidomide\, and Dexamethasone (DRd
 ) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ine
 ligible for Autologous Stem Cell Transplantation (TI-NDMM)\nEstimated prim
 ary completion: 28 April 2031. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06679101
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05552222-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT05552222)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study of T
 eclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and T
 alquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Pa
 rticipants With Newly Diagnosed Multiple Myeloma\nEstimated primary comple
 tion: 30 April 2031. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 lenalidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05552222
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06149286-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT06149286)
DESCRIPTION:Lenalidomide\, phase 3\, Follicular Lymphoma.\nStudy: A Trial t
 o Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Be
 tter Than Rituximab Combined With Lenalidomide in Adult Participants With 
 Follicular Lymphoma and Marginal Zone Lymphoma\nEstimated primary completi
 on: 30 April 2031. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/le
 nalidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06149286
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07299331-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Lenalidomide: Phase na readout est. (NCT07299331)
DESCRIPTION:Lenalidomide\, phase na.\nStudy: Zanubrutinib\, Rituximab\, and
  Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma\nEstim
 ated primary completion: 30 April 2031. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07299331
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05561387-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20310530
DTEND;VALUE=DATE:20310531
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT05561387)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Comparing Co
 mbinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When 
 a Stem Cell Transplant is Not a Medically Suitable Treatment\nEstimated pr
 imary completion: 30 May 2031. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05561387
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05901324-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT05901324)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Efficacy of Lenalidomide Mainte
 nance in Primary Central Nervous System Lymphoma and Primary Vitreoretinal
  Lymphoma: a Phase II\, Open-label\, Single-arm Study\nEstimated primary c
 ompletion: 31 May 2031. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05901324
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285239-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT07285239)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Belantamab M
 afodotin or Daratumumab With Bortezomib\, Lenalidomide and Dexamethasone f
 or Newly Diagnosed Multiple Myeloma\nEstimated primary completion: Novembe
 r 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0728
 5239
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07126236-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20311227
DTEND;VALUE=DATE:20311228
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07126236)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Response-adaptive to Epcoritama
 b In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patie
 nts With Relapse/Refractory Large B Cell Lymphoma\nEstimated primary compl
 etion: 27 December 2031. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07126236
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06182774-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20320131
DTEND;VALUE=DATE:20320201
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT06182774)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Fixed Durati
 on vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Ol
 der Adults With Newly-Diagnosed Multiple Myeloma\nEstimated primary comple
 tion: 31 January 2032. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/lenalidomide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06182774
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05283720-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT05283720)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: A Study to Evaluate Adverse Eve
 nts and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Com
 bination With Oral and Intravenous Anti-Neoplastic Agents in Adult Partici
 pants With Non-Hodgkin Lymphoma\nEstimated primary completion: November 20
 32. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05283720
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06974786-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06974786)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Frontline T-
 cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Resi
 dual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple M
 yeloma\nEstimated primary completion: November 2032. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06974786
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07605416-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20321106
DTEND;VALUE=DATE:20321107
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07605416)
DESCRIPTION:Lenalidomide\, phase 2.\nStudy: Testing an Experimental Approac
 h to Treat Patients With Plasma Cell Leukemia\, The QUANTUM Trial\nEstimat
 ed primary completion: 6 November 2032. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07605416
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06910124-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20321202
DTEND;VALUE=DATE:20321203
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06910124)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Linvoseltama
 b in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to D
 eepen Responses or Redrive MRD Negativity After Relapse\nEstimated primary
  completion: 2 December 2032. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06910124
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05145400-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20330528
DTEND;VALUE=DATE:20330529
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT05145400)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Isa-Rd for F
 rail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma\nEst
 imated primary completion: 28 May 2033. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05145400
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05257083-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT05257083)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study of D
 aratumumab\, Bortezomib\, Lenalidomide and Dexamethasone (DVRd) Followed b
 y Ciltacabtagene Autoleucel Versus Daratumumab\, Bortezomib\, Lenalidomide
  and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASC
 T) in Participants With Newly Diagnosed Multiple Myeloma\nEstimated primar
 y completion: June 2033. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05257083
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07649525-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT07649525)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Personalisin
 g Treatment for Myeloma Patients Based on Initial Response to NHS Treatmen
 t and Their Overall Fitness Level\nEstimated primary completion: June 2033
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07649525
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887984-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20330801
DTEND;VALUE=DATE:20330802
SUMMARY:Lenalidomide: Phase 2/3 readout est. (NCT07887984)
DESCRIPTION:Lenalidomide\, phase 2/3\, Multiple Myeloma.\nStudy: Comparing 
 Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly
  Diagnosed\, Standard Risk Multiple Myeloma\nEstimated primary completion:
  1 August 2033. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenal
 idomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07887984
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05259839-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20330930
DTEND;VALUE=DATE:20331001
SUMMARY:Lenalidomide: Phase 1 readout est. (NCT05259839)
DESCRIPTION:Lenalidomide\, phase 1\, Multiple Myeloma.\nStudy: A Study to A
 ssess Adverse Events and Change in Disease Activity of Intravenously (IV) 
 Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for 
 the Treatment of Adult Participants With Relapsed/Refractory Multiple Myel
 oma\nEstimated primary completion: September 2033. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05259839
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04446962-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20350202
DTEND;VALUE=DATE:20350203
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT04446962)
DESCRIPTION:Lenalidomide\, phase 1/2.\nStudy: LOC-R01 Study of Lenalidomide
  and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vin
 cristin (R-MPV)\nEstimated primary completion: 2 February 2035. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT04446962
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06892522-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT06892522)
DESCRIPTION:Lenalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to
  Assess Change in Disease Activity and Adverse Events (AE)s in Adult Parti
 cipants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific An
 tibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations\n
 Estimated primary completion: December 2035. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06892522
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06918002-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20360531
DTEND;VALUE=DATE:20360601
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT06918002)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Elranatamab/
 Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard 
 of Care After D-VRd Induction in Transplant-eligible NDMM Patients\nEstima
 ted primary completion: May 2036. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06918002
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07600151-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20360930
DTEND;VALUE=DATE:20361001
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT07600151)
DESCRIPTION:Lenalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: Etenta-Isa
 -VRd in Newly Diagnosed High-Risk Multiple Myeloma\nEstimated primary comp
 letion: 30 September 2036. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07600151
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06932562-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20361231
DTEND;VALUE=DATE:20370101
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT06932562)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study to L
 earn How Safe and How Well Linvoseltamab Works Compared to Standard Treatm
 ent in Adult Patients With Multiple Myeloma Who Are Not Eligible for Trans
 plant\nEstimated primary completion: December 2036. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06932562
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06191744-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20371130
DTEND;VALUE=DATE:20371201
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT06191744)
DESCRIPTION:Lenalidomide\, phase 3\, Follicular Lymphoma.\nStudy: Study of 
 Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Ora
 l Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activit
 y in Adult Participants With Previously Untreated Follicular Lymphoma\nEst
 imated primary completion: November 2037. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06191744
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07903506-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20390331
DTEND;VALUE=DATE:20390401
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT07903506)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: To Evaluate 
 Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Ce
 ll Transplant in Newly Diagnosed Multiple Myeloma\nEstimated primary compl
 etion: March 2039. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/le
 nalidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07903506
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887672-3126@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20420228
DTEND;VALUE=DATE:20420301
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT07887672)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Trial to E
 valuate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard o
 f Care in Newly Diagnosed Multiple Myeloma\nEstimated primary completion: 
 February 2042. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenali
 domide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07887672
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
